Active substanceHydrocortisoneHydrocortisone
Similar drugsTo uncover
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment d / eye 
  • Hydrocortisone
    ointment locally 
  • Hydrocortisone
    ointment d / eye 
    SYNTHESIS, OJSC     Russia
  • Hydrocortisone
    suspension w / m in / Sust. 
    FARMAK, JSC     Ukraine
  • Hydrocortisone
    ointment d / eye 
    VALEANT, LLC     Russia
  • Hydrocortisone
    ointment externally 
    AKRIKHIN HFK, JSC     Russia
  • Hydrocortisone
    ointment externally 
    SYNTHESIS, OJSC     Russia
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment externally 
  • Hydrocortisone
    ointment externally 
    BIOSINTEZ, PAO     Russia
  • Hydrocortisone
    ointment externally 
    NIZHFARM, JSC     Russia
  • Hydrocortisone
    ointment externally 
    ATOLL, LLC     Russia
  • Hydrocortisone-POS®
    ointment d / eye 
  • Cortef®
    pills inwards 
    Pfizer Inc.     USA
  • Laticort®
    ointment externally 
    VALEANT, LLC     Russia
  • Laticort®
    cream externally 
    VALEANT, LLC     Russia
  • Laticort®
    solution externally 
    VALEANT, LLC     Russia
  • Lokoid®
    cream externally 
    Astellas Farma Europe BV     Netherlands
  • Lokoid®
    ointment externally 
  • Lokoid Creole®
    emulsion externally 
    Astellas Farma Europe BV     Netherlands
  • Lokoid Lipocream®
    cream externally 
    Astellas Farma Europe BV     Netherlands
  • Solu-Cortef®
    lyophilizate w / m in / in 
  • Dosage form: & nbspointment eye
    Composition:

    1 g eye ointment Hydrocortisone-POS® 1 % contains:

    Active substance: hydrocortisone acetate 10.0 mg Excipients: Vaseline, paraffin liquid, lanolin.

    1 g ointment ointment Hydrocortisone-PIC® 2.5% contains:

    Active substance: hydrocortisone acetate 25.0 mg Excipients: Vaseline, paraffin liquid, lanolin.

    Description:

    White with a yellowish tinge homogeneous suspension ointment.

    Pharmacotherapeutic group:Glucocorticosteroid for topical application
    ATX: & nbsp

    S.01.B.A.02   Hydrocortisone

    H.02.A.B.09   Hydrocortisone

    D.07.A.A.02   Hydrocortisone

    Pharmacodynamics:

    The preparation contains as active substance hydrocortisone acetate glucocorticosteroid.

    When topical application of hydrocortisone acetate suppresses inflammatory and allergic reactions that occur in the area of ​​the outer membranes and anterior segment of the eye.

    The action of hydrocortisone acetate, like other corticosteroids, is based on suppression of the function of leukocytes and tissue macrophages.Limits the migration of leukocytes, macrophages and mast cells to the area of ​​inflammation and suppresses the formation of interleukin-1. Promotes the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the area of ​​inflammation. Reduces the permeability of capillaries due to the release of histamine. Suppresses the activity of fibroblasts and the formation of collagen. Inhibits the activity of phospholipase A2, which leads to suppression of the synthesis of prostaglandins and leukotrienes.

    Pharmacokinetics:Possible penetration of hydrocortisone acetate through the cornea into the moisture of the anterior chamber of the eye due to lipophilic properties. The penetration of hydrocortisone acetate in the tissue depends on the condition of the cornea and is significantly increased in the case of inflammation or damage to the mucosa.
    Indications:

    Allergic conjunctivitis, blepharitis, blepharoconjunctivitis;

    - Acute and chronic iritis, iridocyclitis;

    - Inflammation after surgery on the eyeball;

    - Suppression of neovascularization after the transferred keratitis, chemical burns.

    Contraindications:

    - Hypersensitivity to any component of the drug;

    - Superficial herpes of the cornea and other viral diseases of the eyes;

    - Violations of the integrity of the epithelium and damage to the cornea;

    - Tuberculosis, bacterial or fungal infections of the eyes;

    - Trachoma;

    - Period of vaccination.

    Carefully:Not described.
    Pregnancy and lactation:

    To date, clinical trial data regarding the use of the drug Hydrocortisone-PIC® 1%, 2.5% eye ointment during pregnancy, lactation, and also in children are absent. Hydrocortisone-POC® 1%, 2.5% ophthalmic ointment may be used to treat children over 1 year old, pregnant and nursing mothers as prescribed by the doctor if the expected curative effect exceeds the risk of possible side effects. The duration of the drug in this category of patients is no more than 7-10 days.

    Dosing and Administration:

    In the absence of other recommendations from your doctor, follow these instructions for use of the hydrocortisone-POC® eye ointment 1%, 2.5%.

    A strip of ointment 1 cm long is placed 2-3 times a day for the lower eyelid.

    To do this, open the tube, slightly tilt the head back and lay a strip of ointment 1 cm long behind the lower eyelid. Close your eyes carefully.

    After use, close the tube tightly.

    During the application of ophthalmic ointment, contact with the skin surface or conjunctiva should be avoided.

    When using several eye medicines at the same time, it is recommended to lay Hydrocortisone-POC® eye ointment 1%, 2.5% no earlier than 15 minutes after using eye drops.

    The duration of treatment with Hydrocortisone-POC® ointment ointment is 1%, 2.5% usually does not exceed 2, maximum 3 weeks.

    Side effects:

    If in the treatment with Hydrocortisone-POC® Ointment ointment 1%, 2.5% you develop a side effect not specified in this manual, or you are not sure of the effectiveness of the drug, please inform your doctor or pharmacist.

    In very rare cases, allergic reactions are possible, such as burning, injecting sclera, contact dermatitis, dermatoconjunctivitis, eczema of the eyelids.

    Prolonged use of the drug may cause secondary glaucoma and complicated cataracts, so when using the drug for more than 2 weeks, as well as in patients who have a history of glaucoma, it is recommended to regularly monitor intraocular pressure.

    In case of side effects, stop using the drug and contact the doctor (ophthalmologist) as soon as possible.

    Overdose:When topical application in the recommended dose, the symptoms of an overdose were not noted.
    Interaction:

    The simultaneous use of hydrocortisone-POC® eye ointment 1%, 2.5% and other agents that can cause an increase in intraocular pressure (for example, atropine and other cholinergic drugs) may contribute to an additional increase in intraocular pressure, especially in predisposed patients.

    Special instructions:

    During treatment with Hydrocortisone-POC® ointment eye 1%, 2.5% is not recommended to use contact lenses.

    Effect on the ability to drive transp. cf. and fur:Immediately after application of Hydrocortisone-POC® ointment ointment 1%, 2.5%, a short-term disturbance of visual acuity may occur, leading to a slowing of mental and physical reactions. Therefore, it is not recommended to apply the drug directly before working with mechanisms and driving vehicles.
    Form release / dosage:

    Eye Ointment 1 %, 2.5%.

    Packaging:2.5 grams per tube aluminum, with a polyethylene tip and a screw cap. The tube together with the instruction for use is placed in a cardboard box.
    Storage conditions:

    List B. Store at a temperature of no higher than 25 ° C.

    Keep out of the reach of children!

    Shelf life:

    In closed original packaging: 3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N014922 / 01
    Date of registration:19.12.2007
    Expiration Date:Unlimited
    The owner of the registration certificate:Ursafarm Artsnaymittel GmbHUrsafarm Artsnaymittel GmbH Germany
    Manufacturer: & nbsp
    Representation: & nbspURSAFARM ARTSNAYMITTEL GmbH URSAFARM ARTSNAYMITTEL GmbH Germany
    Information update date: & nbsp07.04.2017
    Illustrated instructions
      Instructions
      Up